Consortium of Eosinophilic Gastrointestinal Disease Researchers

描述(申请人提供)：本申请旨在促进嗜酸性食管炎(EoE)、嗜酸性胃炎(EG)和嗜酸性结肠炎(EC)的研究，通过发展嗜酸性胃肠道疾病研究联盟(CEGIR)。CEGIR由俄亥俄州(协调中心)、科罗拉多州、加利福尼亚州、印第安纳州、宾夕法尼亚州、伊利诺伊州、北卡罗来纳州、马萨诸塞州、瑞士和马里兰州的临床中心组成。所有参与的国内非国立卫生研究院(NIH)临床中心都与临床翻译科学奖(CTSA)有关。CEGIR网站是根据彼此之间先前存在的合作记录精心选择的；多样化 具有相关临床专业的专业知识，包括胃肠病学、过敏、免疫学和病理学；能够将儿科和成人患者整合到一个共同的联合体中；以及在涉及这些患者群体的临床研究方面取得了良好的卓越记录。重要的是，CEGIR网站已经证明可以接触到足够数量的患有所研究的罕见疾病的患者，这从最近完成的涉及这些患者群体的第一组受控临床试验中得到了证明。强大的患者权益倡导团体(PAG)，包括 美国嗜酸性粒细胞疾病伙伴关系(APFED)和敦促研究嗜酸性疾病运动(CREED)已经与CEGIR的研究人员建立了伙伴关系，并将继续在CEGIR的背景下协同工作。尽管CEGIR研究人员最近取得了进展，他们的协作互动取得了早期成功，积极的PAG，以及新型抗嗜酸性粒细胞疗法的开发，但目前还没有现有的资金来建立一个专注于这三种罕见的独特疾病的临床网络，这突显了这一应用的及时性和重要性。

DESCRIPTION (provided by applicant): This application aims to facilitate research on eosinophilic esophagitis (EoE), eosinophilic gastritis (EG), and eosinophilic colitis (EC) through the development of a Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR). CEGIR comprises clinical centers in Ohio (the coordinating center), Colorado, California, Indiana, Pennsylvania, Illinois, North Carolina, Massachusetts, Switzerland, and Maryland. All participating domestic, non-National Institutes of Health (NIH) clinical centers are associated with a Clinical Translational Science Award (CTSA). The CEGIR sites have been carefully chosen on the basis of their preexisting record of collaboration with each other; diverse expertise in relevant clinical specialties including Gastroenterology, Allergy, Immunology, and Pathology; the ability to integrate pediatric and adult patients into a common consortium; and well-established record of excellence in clinical research involving this patient population. Importantly, the CEGIR sites have proven access to an adequate number of patients with the rare diseases studied, as evidenced from the recent completion of the first set of controlled clinical trials involving this patient population. Strong patient advocacy groups (PAGs), including the American Partnership for Eosinophilic Disorders (APFED) and the Campaign Urging Research for Eosinophilic Disease (CURED), already partner with the CEGIR Investigators and will continue to work synergistically in the context of CEGIR. Despite the recent record of advances by CEGIR Investigators, the early success of their collaborative interactions, the proactive PAGs, and the development of novel anti-eosinophil therapeutics, there is no currently existing funding for a clinical network focusing on these three rare, distinct diseases, highlightig the timeliness and importance of this application.